{
    "hands_on_practices": [
        {
            "introduction": "A screening test's intrinsic accuracy, defined by its sensitivity ($Se$) and specificity ($Sp$), is only part of the story. This practice demonstrates the critical role of disease prevalence in determining the real-world meaning of a test result. By deriving and calculating the Positive Predictive Value ($PPV$) and Negative Predictive Value ($NPV$), you will gain a practical understanding of why even a highly accurate test can yield a surprisingly high number of false positives in a low-prevalence population, a crucial insight for any screening program evaluation .",
            "id": "4374026",
            "problem": "A public health department is evaluating a new screening test for a chronic condition in a defined adult population enrolled in a primary care network. In this population, the condition’s prevalence is $p=0.03$. The test has sensitivity $Se=0.92$ and specificity $Sp=0.97$. Using only the fundamental definitions of sensitivity ($Se=P(\\text{Test}+\\mid \\text{Disease})$), specificity ($Sp=P(\\text{Test}-\\mid \\neg \\text{Disease})$), and prevalence ($p=P(\\text{Disease})$), together with the law of total probability and Bayes’ Theorem, derive expressions for the positive predictive value (PPV) and negative predictive value (NPV), then compute their values for the given parameters. Finally, interpret the clinical meanings of the computed $PPV$ and $NPV$ in terms of probabilities of disease given test results in this screening context. Report the ordered pair $\\left(PPV,NPV\\right)$ as decimals without percent symbols, rounded to four significant figures.",
            "solution": "The problem is subjected to validation before a solution is attempted.\n\n### Step 1: Extract Givens\n- Prevalence of the condition: $p = P(\\text{Disease}) = 0.03$.\n- Sensitivity of the test: $Se = P(\\text{Test}+\\mid \\text{Disease}) = 0.92$.\n- Specificity of the test: $Sp = P(\\text{Test}-\\mid \\neg \\text{Disease}) = 0.97$.\n- The task is to derive expressions for the positive predictive value ($PPV$) and negative predictive value ($NPV$) using Bayes' Theorem and the law of total probability, compute their numerical values, interpret the results, and report the ordered pair $(PPV, NPV)$ rounded to four significant figures.\n\n### Step 2: Validate Using Extracted Givens\n1.  **Scientific or Factual Unsoundness**: The problem statement is scientifically sound. It uses standard, well-defined concepts from epidemiology and biostatistics (prevalence, sensitivity, specificity, PPV, NPV) and their relationships as described by Bayes' Theorem. The provided numerical values are realistic for a medical screening test.\n2.  **Non-Formalizable or Irrelevant**: The problem is formalizable using the axioms and theorems of probability theory. It is directly relevant to the field of health systems science, specifically concerning the evaluation of screening programs.\n3.  **Incomplete or Contradictory Setup**: The problem is self-contained. The provided parameters ($p$, $Se$, $Sp$) are precisely the information required to calculate $PPV$ and $NPV$. There are no contradictions.\n4.  **Unrealistic or Infeasible**: The conditions and data are realistic and scientifically plausible. A prevalence of $3\\%$ is common for many chronic conditions, and sensitivity/specificity values in the high $90$s are typical goals for good screening tests.\n5.  **Ill-Posed or Poorly Structured**: The problem is well-posed. It has a clear objective and provides all necessary information to arrive at a unique, meaningful solution.\n6.  **Pseudo-Profound, Trivial, or Tautological**: The problem requires a correct application of fundamental theorems, which is a non-trivial exercise demonstrating conceptual understanding. It is a standard and important application of probability theory.\n7.  **Outside Scientific Verifiability**: The calculations and derivations are mathematically verifiable.\n\n### Step 3: Verdict and Action\nThe problem is valid. A complete solution will be provided.\n\n### Derivation and Solution\nLet $D$ denote the event that an individual has the disease, and $\\neg D$ denote the event that the individual does not have the disease. Let $T+$ denote a positive test result and $T-$ denote a negative test result.\n\nThe given information can be written as:\n- Prevalence: $P(D) = p = 0.03$. From this, the probability of not having the disease is $P(\\neg D) = 1 - p = 1 - 0.03 = 0.97$.\n- Sensitivity: $Se = P(T+ | D) = 0.92$.\n- Specificity: $Sp = P(T- | \\neg D) = 0.97$.\n\nFrom these, we can also deduce the probabilities of the complementary conditional events:\n- False Negative Rate: $P(T- | D) = 1 - P(T+ | D) = 1 - Se = 1 - 0.92 = 0.08$.\n- False Positive Rate: $P(T+ | \\neg D) = 1 - P(T- | \\neg D) = 1 - Sp = 1 - 0.97 = 0.03$.\n\n**1. Derive the Positive Predictive Value (PPV)**\nThe $PPV$ is the probability that an individual with a positive test result actually has the disease, i.e., $PPV = P(D | T+)$.\nUsing Bayes' Theorem:\n$$PPV = P(D | T+) = \\frac{P(T+ | D) P(D)}{P(T+)}$$\nThe numerator is the product of the sensitivity and the prevalence: $P(T+ | D) P(D) = Se \\cdot p$.\nThe denominator, $P(T+)$, is the overall probability of a positive test. We find this using the law of total probability:\n$$P(T+) = P(T+ | D) P(D) + P(T+ | \\neg D) P(\\neg D)$$\nSubstituting the known terms:\n$$P(T+) = (Se \\cdot p) + ((1 - Sp) \\cdot (1 - p))$$\nCombining these, the general expression for $PPV$ is:\n$$PPV = \\frac{Se \\cdot p}{(Se \\cdot p) + (1 - Sp)(1 - p)}$$\n\n**2. Derive the Negative Predictive Value (NPV)**\nThe $NPV$ is the probability that an individual with a negative test result is truly disease-free, i.e., $NPV = P(\\neg D | T-)$.\nUsing Bayes' Theorem:\n$$NPV = P(\\neg D | T-) = \\frac{P(T- | \\neg D) P(\\neg D)}{P(T-)}$$\nThe numerator is the product of the specificity and the probability of not having the disease: $P(T- | \\neg D) P(\\neg D) = Sp \\cdot (1 - p)$.\nThe denominator, $P(T-)$, is the overall probability of a negative test. Using the law of total probability:\n$$P(T-) = P(T- | \\neg D) P(\\neg D) + P(T- | D) P(D)$$\nSubstituting the known terms:\n$$P(T-) = (Sp \\cdot (1 - p)) + ((1 - Se) \\cdot p)$$\nCombining these, the general expression for $NPV$ is:\n$$NPV = \\frac{Sp \\cdot (1 - p)}{(Sp \\cdot (1 - p)) + (1 - Se)p}$$\n\n**3. Compute Numerical Values**\nUsing the given parameters: $p = 0.03$, $Se = 0.92$, and $Sp = 0.97$.\n\nFor $PPV$:\n$$PPV = \\frac{0.92 \\cdot 0.03}{(0.92 \\cdot 0.03) + (1 - 0.97)(1 - 0.03)}$$\n$$PPV = \\frac{0.0276}{0.0276 + (0.03)(0.97)}$$\n$$PPV = \\frac{0.0276}{0.0276 + 0.0291}$$\n$$PPV = \\frac{0.0276}{0.0567} \\approx 0.48677248677$$\nRounded to four significant figures, $PPV = 0.4868$.\n\nFor $NPV$:\n$$NPV = \\frac{0.97 \\cdot (1 - 0.03)}{(0.97 \\cdot (1 - 0.03)) + (1 - 0.92)(0.03)}$$\n$$NPV = \\frac{0.97 \\cdot 0.97}{(0.97 \\cdot 0.97) + (0.08)(0.03)}$$\n$$NPV = \\frac{0.9409}{0.9409 + 0.0024}$$\n$$NPV = \\frac{0.9409}{0.9433} \\approx 0.99745574048$$\nRounded to four significant figures, $NPV = 0.9975$.\n\n**4. Interpretation of Clinical Meanings**\n- **PPV = 0.4868**: In this specific population, if an individual receives a positive screening test result, there is a $48.68\\%$ probability that they actually have the chronic condition. This indicates that a positive result is almost as likely to be a false positive (a probability of $1 - 0.4868 = 0.5132$ or $51.32\\%$) as it is to be a true positive. This is a common finding for screening tests in low-prevalence populations and underscores the need for confirmatory diagnostic testing following a positive screen.\n- **NPV = 0.9975**: If an individual from this population receives a negative screening test result, there is a $99.75\\%$ probability that they are truly free of the condition. This very high $NPV$ indicates that a negative result is extremely reliable for ruling out the disease in this context. It provides a high degree of reassurance to the patient and clinician.\n\nThe ordered pair of computed values is $(PPV, NPV) = (0.4868, 0.9975)$.",
            "answer": "$$\n\\boxed{\n\\begin{pmatrix}\n0.4868 & 0.9975\n\\end{pmatrix}\n}\n$$"
        },
        {
            "introduction": "When a new screening program reports a dramatic increase in survival rates, it may seem like an unambiguous success. This exercise challenges you to think like an epidemiologist, looking beyond surface-level statistics to diagnose the potential impact of screening biases. By analyzing a scenario where survival improves but population mortality does not, you will learn to identify the classic signatures of lead-time bias, length-time bias, and overdiagnosis, which are essential skills for critically appraising the true effectiveness of health interventions .",
            "id": "4374115",
            "problem": "A public health authority implements a statewide screening program for a cancer with a long preclinical phase. Prior to the program, the annual disease-specific mortality rate was $30$ per $100{,}000$ population, the incidence was $50$ per $100{,}000$ population per year, and $5$-year survival among diagnosed cases was $40\\%$. Five years after the program begins, coverage reaches $80\\%$ of eligible adults aged $50$ to $74$. The new metrics are: annual disease-specific mortality rate remains $30$ per $100{,}000$ population, incidence increases to $80$ per $100{,}000$ population per year, and $5$-year survival among diagnosed cases increases to $65\\%$. No new therapies or major changes in access to treatment occur during this period.\n\nUsing fundamental definitions from population epidemiology and screening science, identify which biases most plausibly explain this pattern and justify your choice. In your reasoning, you must explicitly use the following foundational bases without invoking shortcut formulas:\n\n- The population disease-specific mortality rate is defined as the expected number of deaths attributed to the disease per unit time per unit population, which depends on the true risk of death from the disease among all individuals, not only those diagnosed.\n- The case survival proportion at $5$ years is defined as $S_5 = \\Pr(T \\ge 5 \\mid \\text{diagnosed at time } t_0)$, where $T$ is time from diagnosis to death from the disease or censoring.\n- Screening moves the time of diagnosis earlier in the disease natural history if disease is present in the preclinical phase.\n- Screening may detect a spectrum of disease with varying growth rates.\n\nWhich option best fits the observed pattern?\n\nA. Lead-time bias and overdiagnosis bias are most consistent; length-time bias may contribute.\n\nB. Confounding by improved treatment and selection bias among screened participants exclusively.\n\nC. Measurement error in cause-of-death coding causing artifactual survival increase without mortality change.\n\nD. Lead-time bias alone fully explains all findings including increased incidence.\n\nE. Length-time bias alone explains unchanged mortality with increased survival and incidence.",
            "solution": "The problem statement will first be validated for scientific soundness, clarity, and completeness.\n\n**Step 1: Extract Givens**\n-   **Subject**: A statewide screening program for a cancer with a long preclinical phase.\n-   **Baseline (Pre-Program) Data**:\n    -   Annual disease-specific mortality rate: $30$ per $100{,}000$ population.\n    -   Annual incidence rate: $50$ per $100{,}000$ population.\n    -   $5$-year survival among diagnosed cases: $40\\%$.\n-   **Follow-up (Post-Program) Data**:\n    -   Screening coverage: $80\\%$ of eligible adults aged $50$ to $74$.\n    -   Annual disease-specific mortality rate: $30$ per $100{,}000$ population (unchanged).\n    -   Annual incidence rate: $80$ per $100{,}000$ population (increased).\n    -   $5$-year survival among diagnosed cases: $65\\%$ (increased).\n-   **Conditions and Foundational Principles**:\n    -   The period saw no new therapies or major changes in access to treatment.\n    -   Population mortality is the true risk of death from the disease across the entire population.\n    -   $5$-year survival is defined as $S_5 = \\Pr(T \\ge 5 \\mid \\text{diagnosed at time } t_0)$.\n    -   Screening moves the time of diagnosis earlier in the disease's natural history.\n    -   Screening may detect a spectrum of disease with varying growth rates.\n\n**Step 2: Validate Using Extracted Givens**\nThe problem is scientifically and logically sound.\n-   **Scientifically Grounded**: The problem presents a classic and realistic scenario in epidemiology for evaluating the impact of a cancer screening program. The concepts of incidence, mortality, survival, and screening biases (lead-time, length-time, overdiagnosis) are fundamental to public health and epidemiology. The data values are plausible.\n-   **Well-Posed**: The problem is clearly stated. It provides a set of initial conditions and a set of final observations, asking for the most plausible explanation based on a defined set of principles. A unique and meaningful answer can be derived.\n-   **Objective**: The problem is described using quantitative data and established scientific definitions. It is free from subjective language.\n-   The problem setup is internally consistent and complete. The central paradox—improved intermediate outcomes (incidence, survival) with no change in the ultimate outcome (mortality)—is a well-known phenomenon that directly points toward screening biases, which is the subject of the question.\n\n**Step 3: Verdict and Action**\nThe problem statement is valid. A full solution will be derived.\n\n**Derivation of the Solution**\n\nThe core of the problem is to explain why the $5$-year survival rate and incidence rate increased, while the population-wide disease-specific mortality rate remained constant, in the absence of new, more effective treatments. This pattern is a strong indicator that the apparent benefits of the screening program are due to statistical artifacts and biases, rather than a true reduction in deaths from the cancer. We must analyze the observed changes in the context of the provided foundational principles.\n\n1.  **Analysis of Unchanged Mortality Rate**:\n    The disease-specific mortality rate for the entire population is the most robust measure of a screening program's effectiveness. The problem states this rate remained constant at $30$ per $100{,}000$. If the screening program were successfully enabling cures that would not have otherwise occurred, there would be a detectable decrease in the number of people dying from the disease in the population, causing this rate to fall. Since it did not, we must conclude that the program, despite its other effects, is not saving more lives than were being saved before its implementation. The \"improvements\" seen in other metrics must therefore be artifactual.\n\n2.  **Analysis of Increased $5$-Year Survival (from $40\\%$ to $65\\%$):**\n    The $5$-year survival is the proportion of diagnosed individuals who are still alive $5$ years after diagnosis. A dramatic increase from $40\\%$ to $65\\%$ can be explained by several biases, especially when mortality is unchanged.\n    -   **Lead-Time Bias**: The problem states screening moves the time of diagnosis earlier. Let's denote the time of diagnosis by screening as $t_{screen}$ and the time of diagnosis by clinical symptoms as $t_{clinical}$. The time of death is $t_{death}$. By definition, $t_{screen}  t_{clinical}$. Before the program, survival was measured as $t_{death} - t_{clinical}$. With screening, survival is measured as $t_{death} - t_{screen}$. Since $t_{screen}  t_{clinical}$, the measured survival time $(t_{death} - t_{screen})$ is greater than $(t_{death} - t_{clinical})$ even if the time of death, $t_{death}$, is completely unchanged by the intervention. This artifactual increase in survival time is known as lead-time bias. It directly contributes to an increased $5$-year survival proportion without any change in the date of death.\n    -   **Length-Time Bias**: The problem states screening can detect diseases with varying growth rates. Cancers are heterogeneous; some are aggressive and fast-growing, while others are indolent and slow-growing. Slow-growing cancers have a longer asymptomatic preclinical phase. A periodic screening test is more likely to fall within this longer window and detect a slow-growing cancer than it is to fall within the shorter window of a fast-growing cancer. Consequently, the group of screen-detected cases is enriched with slower-growing, more indolent tumors, which have an inherently better prognosis and longer survival, regardless of treatment. This selection for \"better\" cancers artifactually inflates the average survival rate of the diagnosed cohort.\n    -   **Overdiagnosis Bias**: This is a related and extreme form of length-time bias. Overdiagnosis is the detection of cancers that would never have progressed to cause symptoms or death in the person's lifetime. These are often pathologically confirmed cancers but are biologically non-progressive or so slow-growing that the person would die of other causes first. When these cases are detected and added to the cancer registry, they are included in the denominator of the survival calculation. Since these individuals were never going to die from this cancer, they have nearly $100\\%$ $5$-year survival from the disease. Adding a large number of these \"perfect survival\" cases to the cohort of diagnosed patients mathematically guarantees that the overall average survival rate will increase.\n\n3.  **Analysis of Increased Incidence (from $50$ to $80$ per $100{,}000$ per year):**\n    The incidence rate increased by $(80-50)/50 = 60\\%$. This is a substantial rise.\n    -   While a new screening program will initially cause an incidence spike by detecting a pool of existing (prevalent) undiagnosed cases, an ongoing program should settle into a rate that reflects the true rate of disease onset. A sustained increase of this magnitude cannot be explained by lead-time bias alone (which just diagnoses the same cases earlier).\n    -   The most powerful explanation for a large, sustained increase in incidence in the context of screening is **overdiagnosis**. The program is labeling cellular abnormalities as \"cancer\" that would have otherwise remained subclinical for the person's entire life. These are new \"cases\" that would never have been counted in the pre-screening era, thus directly and significantly increasing the measured incidence rate.\n\n**Synthesis and Evaluation of Options**\n\nThe combination of a stable mortality rate, a sharply increased survival rate, and a sharply increased incidence rate is the classic signature of a screening program that is causing significant overdiagnosis and is subject to lead-time bias.\n\n-   **Lead-time bias** is certainly present, as it is an inherent property of early detection. It is a major contributor to the increased survival statistic.\n-   **Overdiagnosis bias** is the most compelling explanation for the large increase in incidence, and it also contributes strongly to the increased survival rate. The fact that mortality is unchanged is the key evidence that many of these \"new\" cases are not life-threatening.\n-   **Length-time bias** is also likely contributing to the increased survival by preferentially detecting more indolent tumors, but overdiagnosis is a more specific and powerful concept needed to explain the large magnitude of the incidence increase.\n\nNow, we evaluate the given options based on this analysis.\n\n**A. Lead-time bias and overdiagnosis bias are most consistent; length-time bias may contribute.**\nThis option correctly identifies the two primary biases that explain the full pattern of observations. Lead-time bias explains the artifactual increase in survival time. Overdiagnosis explains both the large increase in incidence and contributes to the increased survival rate. Both are consistent with the unchanged mortality rate. It also correctly notes that length-time bias is a plausible contributing factor. This is the most complete and accurate explanation.\n**Verdict: Correct**\n\n**B. Confounding by improved treatment and selection bias among screened participants exclusively.**\nThis option is incorrect. The problem explicitly states \"No new therapies or major changes in access to treatment occur,\" which rules out confounding by improved treatment. While selection bias (e.g., healthier people get screened) might exist, it is not the primary or exclusive explanation for the specific combination of a $60\\%$ incidence rise and unchanged population mortality. The biases intrinsic to the screening process (lead-time, overdiagnosis) are far more direct explanations.\n**Verdict: Incorrect**\n\n**C. Measurement error in cause-of-death coding causing artifactual survival increase without mortality change.**\nThis option presents a contradiction. If cause-of-death coding changed such that fewer deaths were attributed to the cancer, the measured disease-specific mortality rate would decrease. The problem states this rate was unchanged at $30$ per $100{,}000$. Therefore, this explanation is inconsistent with the provided data.\n**Verdict: Incorrect**\n\n**D. Lead-time bias alone fully explains all findings including increased incidence.**\nThis is an incomplete explanation. Lead-time bias explains why measured survival time increases when diagnosis is brought forward. However, it does not explain why the number of new cases diagnosed per year would increase by $60\\%$. Diagnosing the same destined-to-be-clinical cases earlier does not, in itself, create more cases. The large increase in incidence requires another explanation, namely overdiagnosis.\n**Verdict: Incorrect**\n\n**E. Length-time bias alone explains unchanged mortality with increased survival and incidence.**\nWhile length-time bias contributes to increased survival (by finding slow-growing tumors) and can contribute to a modest increase in incidence, it is unlikely to be the sole explanation for a massive $60\\%$ increase in incidence. Overdiagnosis, the detection of non-progressive disease, is a more direct and powerful explanation for such a large jump in case numbers. Thus, stating length-time bias *alone* is the explanation is insufficient.\n**Verdict: Incorrect**",
            "answer": "$$\\boxed{A}$$"
        },
        {
            "introduction": "Real-world decisions on implementing a population-wide screening program require a holistic balancing of potential benefits against the inevitable harms and costs. This advanced practice guides you through the construction of a decision analysis model to quantify the program's overall value. You will synthesize concepts like test accuracy, disease prevalence, treatment effectiveness, and the disutilities from the screening process itself—including procedural harms and anxiety from false positives—into a single, powerful metric: the net expected Quality-Adjusted Life Years (QALYs) .",
            "id": "4374157",
            "problem": "A public health system is evaluating a one-time population screening program for an asymptomatic chronic disease in adults. The decision problem is to compute the expected net benefit of screening per $1000$ individuals, measured in Quality-Adjusted Life Years (QALYs), where a Quality-Adjusted Life Year (QALY) weights length of life by health-related quality of life on a $0$ to $1$ scale. Build the expected value using a simple decision tree that captures the following, and then compute the expected net QALYs per $1000$ screened:\n\n- Disease prevalence in the target population is $p = 0.02$.\n- The screening test has sensitivity $\\text{Se} = 0.85$ and specificity $\\text{Sp} = 0.90$.\n- All individuals with a positive screening result undergo a single confirmatory diagnostic procedure that is perfectly accurate. This procedure imposes a base disutility of $h_{\\text{diag}} = 0.005$ QALYs per person undergoing it and carries an independent serious complication risk of $r = 0.001$ that causes an additional QALY loss of $c = 0.2$ if it occurs.\n- Each screened individual incurs a one-time disutility of $s = 0.0002$ QALYs from the screening test itself.\n- Individuals with a false-positive screening result experience a transient anxiety disutility of $a_{\\text{fp}} = 0.002$ QALYs prior to receiving their confirmatory result.\n- Individuals with a true-positive screening result who are confirmed to have disease are offered treatment. The average QALY gain from earlier detection and treatment, if adhered to and effective, is $b = 0.6$ per such individual. Among confirmed true-positive individuals, the probability of treatment adherence is $a_{\\text{treat}} = 0.7$, and the probability that treatment is effective conditional on adherence is $e = 0.8$. Individuals who do not adhere or whose treatment is ineffective realize no QALY gain from screening.\n- There is no overdiagnosis in this scenario, and there are no additional benefits or harms beyond those specified.\n\nUse the fundamental definitions of sensitivity, specificity, prevalence, and expected value. Construct the expected net QALY per $1000$ screened as total expected QALY gains minus total expected QALY losses across all branches of the decision tree. Round your final answer to four significant figures. Express the final expected net benefit in QALYs per $1000$ screened.",
            "solution": "The problem is evaluated as valid, as it is scientifically grounded in decision analysis and health economics, self-contained, well-posed, and free of the specified flaws. We proceed to provide a complete solution.\n\n### Step 1: Define Cohort and Subgroups\nWe will model the outcomes for a cohort of $N=1000$ individuals.\n-   Prevalence of disease, $p = 0.02$.\n-   Sensitivity, $\\text{Se} = 0.85$.\n-   Specificity, $\\text{Sp} = 0.90$.\n\nFirst, we calculate the number of individuals in the four fundamental subgroups of a screening test:\n-   Number with disease ($N_D$) = $1000 \\times 0.02 = 20$.\n-   Number without disease ($N_{ND}$) = $1000 \\times (1 - 0.02) = 980$.\n\nFrom these, we find the number of true positives (TP), false negatives (FN), false positives (FP), and true negatives (TN):\n-   $N_{TP} = N_D \\times \\text{Se} = 20 \\times 0.85 = 17$. These individuals test positive and have the disease.\n-   $N_{FN} = N_D \\times (1 - \\text{Se}) = 20 \\times 0.15 = 3$. These have the disease but test negative and receive no further intervention in the model.\n-   $N_{FP} = N_{ND} \\times (1 - \\text{Sp}) = 980 \\times 0.10 = 98$. These are healthy but test positive.\n-   $N_{TN} = N_{ND} \\times \\text{Sp} = 980 \\times 0.90 = 882$. These are healthy and test negative.\nCheck: $17 + 3 + 98 + 882 = 1000$.\n\n### Step 2: Calculate Total QALY Gains\nThe only QALY gains come from true positives who are successfully treated.\n-   Treatment adherence probability, $a_{\\text{treat}} = 0.7$.\n-   Treatment effectiveness probability, $e = 0.8$.\n-   QALY gain per successful treatment, $b = 0.6$.\n\nNumber of successfully treated individuals = $N_{TP} \\times a_{\\text{treat}} \\times e = 17 \\times 0.7 \\times 0.8 = 9.52$.\nTotal QALY Gain = $9.52 \\times b = 9.52 \\times 0.6 = 5.712$ QALYs.\n\n### Step 3: Calculate Total QALY Losses (Disutilities)\nWe sum the harms across the different branches of the decision tree.\n\n1.  **Screening Disutility**: Affects all $1000$ individuals.\n    -   Loss = $1000 \\times s = 1000 \\times 0.0002 = 0.2$ QALYs.\n\n2.  **Diagnostic Procedure Disutility**: Affects all screen-positives ($N_{TP} + N_{FP} = 17 + 98 = 115$).\n    -   Base loss from procedure = $115 \\times h_{\\text{diag}} = 115 \\times 0.005 = 0.575$ QALYs.\n    -   Expected loss from complications = $115 \\times r \\times c = 115 \\times 0.001 \\times 0.2 = 0.023$ QALYs.\n\n3.  **False-Positive Anxiety Disutility**: Affects the $98$ false positives.\n    -   Loss = $N_{FP} \\times a_{\\text{fp}} = 98 \\times 0.002 = 0.196$ QALYs.\n\nTotal QALY Loss = $0.2 + 0.575 + 0.023 + 0.196 = 0.994$ QALYs.\n\n### Step 4: Calculate Net Expected QALYs\nThe net benefit is the total gain minus the total loss for the cohort of $1000$.\nNet QALYs = Total QALY Gain - Total QALY Loss\nNet QALYs = $5.712 - 0.994 = 4.718$ QALYs.\n\nThe final answer, rounded to four significant figures, is $4.718$ QALYs per $1000$ screened.",
            "answer": "$$\n\\boxed{4.718}\n$$"
        }
    ]
}